Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells

Bone

Volumn 25, Issue 3, 1999, Pages 255-259

  Hofbauer, L C ^a   Lacey, D L ^c   Dunstan, C R ^c   Spelsberg, T C ^b   Riggs, B L ^a   Khosla, S ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c AMGEN INC   (United States)

Author keywords

IL 6; Interleukin (IL) 1 ; Osteoblast; Osteoprotegerin; Osteoprotegerin ligand; Tumor necrosis factor (TNF )

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CARRIER PROTEIN; INTERLEUKIN 1; LIGAND; MEMBRANE PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOSARCOMA CELL; BIOSYNTHESIS; BONE MARROW CELL; CELL CULTURE; CELL LINE; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NORTHERN BLOTTING; OSTEOBLAST;

BLOTTING, NORTHERN; BONE MARROW CELLS; CARRIER PROTEINS; CELL LINE, TRANSFORMED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; LIGANDS; MEMBRANE GLYCOPROTEINS; OSTEOBLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032588998     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(99)00162-3     Document Type: Article

References (38)

1. Anderson M.A., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390:1997;175-179.
2. Borden P., Heller R.A. Transcriptional control of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryot Gene Exp. 7:1997;159-178.
3. 2 in human bone marrow stroma cells. Biochem Biophys Res Commun. 247:1998;338-341.
4. Brändström H., Jonsson K.B., Vidal O., Ljunghall S., Ohlsson C., Ljunggren Ö. Tumor necrosis factor-α and -β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun. 248:1998;454-457.
5. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., Boyle W.J., Simonet W.S. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1998;1260-1268.
6. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood. 87:1996;2095-2147.
7. Feinberg A.P., Vogelstein B. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 132:1983;6-13.
8. Fuller K., Wong B., Fox S., Choi Y., Chambers T.J. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med. 188:1998;997-1001.
9. Hicok K.C., Thomas T., Gori F., Rickard D.J., Spelsberg T.C., Riggs B.L. Development and characterization of conditionally immortalized osteoblast precursor cell lines from human bone marrow stroma. J Bone Miner Res. 13:1998;205-217.
10. Hing L., Carlson L., Siebenlist U., Boyce B.F. Mechanisms by which NF-κB regulates osteoclast numbers. Bone. 23:(Suppl. 1):1998;S190.
11. Hofbauer L.C., Heufelder A.E. Osteoprotegerin and its cognate ligand New paradigm of osteoclastogenesis . Eur J Endocrinol. 139:1998;152-154.
12. Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Riggs B.L., Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun. 250:1998;776-781.
13. Hofbauer, L. C., Riggs, B. L., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., and Khosla, S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. In press.
14. Hofbauer L.C., Khosla S., Dunstan C.R., Spelsberg T.C., Riggs B.L. Estrogen stimulates production of the antiresorptive cytokine receptor osteoprotegerin in human osteoblastic cells. Bone. 23:(Suppl. 1):1998;S172.
15. Jilka R.L. Cytokines, bone remodeling, and estrogen deficiency A 1998 update . Bone. 23:1998;75-81.
16. Kassem M., Khosla S., Spelsberg T.C., Riggs B.L. Cytokine production in the bone marrow microenvironment Failure to demonstrate estrogen regulation in early postmenopausal women . J Clin Endocrinol Metab. 81:1996;513-518.
17. Kimble R.B., Srivastava S., Ross F.P., Matayoshi A., Pacifici R. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor. J Biol Chem. 271:1996;28890-28897.
18. Kong Y.-Y., Yoshida H., Sarosi I., Tan H.-L., Timms E., Capparelli C., Morony S., Oliviera-Dos Santos A.J., Van G., Itie A., Khoo W., Wakeham A., Dunstan C.R., Lacey D.L., Mak T.W., Boyle W.J., Penninger J. OPGL is a key regulator of osteoclastogenesis, lymphocyte development, and lymph-node organogenesis. Nature. 397:1999;315-323.
19. Kwon B.S., Wang S., Udagawa N., Haridas V., Lee Z.H., Kim K.K., Oh K.-O., Greene J., Li Y., Su J., Gentz R., Aggarwal B.B., Ni J. TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J. 12:1998;845-854.
20. Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.-X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:1998;165-176.
21. Lehrach H., Diamond D., Wozney J.M., Boedtker H. RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexamination. Biochemistry. 16:1977;4743-4751.
22. Manolagas S.C., Jilka R.L. Bone marrow, cytokines, and bone remodeling Emerging insights into the pathophysiology of osteoporosis . N Engl J Med. 332:1995;305-311.
23. Mizuno A., Amizuka N., Irie K., Murakami A., Fujise N., Kanno T., Sato Y., Nakagawa N., Yasuda H., Mochizuki S., Gomibuchi T., Yano K., Shima N., Washida N., Tsuda E., Morinaga T., Higashio K., Ozawa H. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun. 247:1998;610-615.
24. Nishimura R., Moriyama K., Yasukawa K., Mundy G.R., Yoneda T. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. J Bone Miner Res. 13:1998;777-785.
25. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res. 11:1996;1043-1051.
26. Quinn J.M.W., Elliott J., Gillespie M.T., Martin T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology. 139:1998;4424-4427.
27. Romas E., Udagawa N., Zhou H., Tamura T., Saito M., Taga T., Hilton D.J., Suda T., Ng K.W., Martin T.J. The role of gp130-mediated signals in osteoclast development Regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures . J Exp Med. 183:1996;2581-2591.
28. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.-S., Lüthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Eliott R., Colombero A., Tan H.-L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Osteoprotegerin A novel secreted protein involved in the regulation of bone density . Cell. 89:1997;309-319.
29. Takai H., Kanematsu M., Yano K., Tsuda E., Higashio K., Ikeda K., Watanabe K., Yamada Y. Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem. 273:1998;27091-27096.
30. Tan K.B., Harrop J., Reddy M., Young P., Terrett J., Emery J., Moore G., Truneh A. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene. 204:1997;35-46.
31. Thomas P.S. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci USA. 77:1980;5201-5205.
32. 2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun. 246:1998;337-341.
33. van Deuren M., van der Ven-Jongekeijg J., Vannier E., van Dalen R., Pesman G., Bartelink A.K., Dinarello C.A., van der Meer J.W. The pattern of interleukin-1beta (IL-1beta) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections. Blood. 90:1997;1101-1108.
34. Vidal N.O.A., Brändström H., Jonsson K.B., Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells Down-regulation by glucocorticoids . J Endocrinol. 159:1998;191-195.
35. Vidal O.N.A., Sjögren K., Eriksson B.I., Ljunggren Ö., Ohlsson C. Osteoprotegerin mRNA is increased by interleukin-α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem Biophys Res Commun. 248:1998;696-700.
36. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F.S., Frankel W.N., Young Lee S., Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells. J Biol Chem. 272:1997;25190-25194.
37. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S.-I., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:1998;3597-3602.
38. Yasuda H., Shima N., Nakagawa N., Mochizuki S.-I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG) A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro . Endocrinology. 139:1998;1329-1337.